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Background-—Advanced cardiac imaging permits optimal targeting of cardiac treatment but needs to be faster, cheaper, and easier
for global delivery. We aimed to pilot rapid cardiac magnetic resonance (CMR) with contrast in a developing nation, embedding it
within clinical care along with training and mentoring.
Methods and Results-—A cross-sectional study of CMR delivery and clinical impact assessment performed 2016–2017 in an upper
middle-income country. An International partnership (clinicians in Peru and collaborators from the United Kingdom, United States,
Brazil, and Colombia) developed and tested a 15-minute CMR protocol in the United Kingdom, for cardiac volumes, function and
scar, and delivered it with reporting combined with training, education and mentoring in 2 centers in the capital city, Lima, Peru,
100 patients referred by local doctors from 6 centers. Management changes related to the CMR were reviewed at 12 months.
One-hundred scans were conducted in 98 patients with no complications. Final diagnoses were cardiomyopathy (hypertrophic,
26%; dilated, 22%; ischemic, 15%) and 12 other pathologies including tumors, congenital heart disease, iron overload, amyloidosis,
genetic syndromes, vasculitis, thrombi, and valve disease. Scan cost was $150 USD, and the average scan duration was
187 minutes. Findings impacted management in 56% of patients, including previously unsuspected diagnoses in 19% and
therapeutic management changes in 37%.
Conclusions-—Advanced cardiac diagnostics, here CMR with contrast, is possible using existing infrastructure in the
developing world in 18 minutes for $150, resulting in important changes in patient care. ( J Am Heart Assoc. 2018;7:
e008981. DOI: 10.1161/JAHA.118.008981.)
Key Words: cardiac magnetic resonance • effectiveness • impact on patient management • outcome • rapid cardiac magnetic
resonance
C ardiovascular disease (CVD) is the leading cause of deathin developed countries, accounting for 17.9 million
deaths per year causing 30% of global deaths.1 However, CVD
disease and death rates are highest in low- and middle-income
countries, despite there being a lower burden of classical risk
factors.2–4 For example, in Peru, CVD affects 3.2 million (16% of
the adult population), leading to a signiﬁcant loss of well-being,
estimated at 281 829 Disability Adjusted Life Years. The age-
standardized death rate is 142 per 100 000 inhabitants,
resulting in productivity losses of 0.69 bnUSD and health costs
of 0.24 bn USD, representing 2.1% of total health spending,
which the country can ill afford.5,6
A key aspect of cardiovascular care is diagnostic testing.
Without this, clinical care is inefﬁcient at best, inaccurate or
mistaken at worst. The hierarchy of diagnostic testing is used
optimally by employing guidance and care pathways, taking into
account local resource availability and cost constraints. Cardiac
magnetic resonance (CMR) imaging is an emerging imaging
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technique with the capacity to transform cardiology in an
analogous way to the impact of brain MRI in neurology.7,8
Multiple different techniques are available using CMR (function,
scar, perfusion, ﬂow, mapping, angiography), delivering valu-
able clinical insights with the potential of a high impact.9–11
However, these varied techniques may make it slow (typically
45 minutes), expensive and complex, potentially out of reach
for most inhabitants in the developing world. In Peru, although
MRI scanners are available for other indications, just 2 public
hospitals undertake CMR, performing a total of 6 scans per
week (1 scan per million population per year), at a cost of
$400 to $800. This compares to the United Kingdom where
there are60 UK centers performing1000 scans per million
population per year, at a cost of $640.12 However, we contend
that CMR could be made faster, cheaper, and easier, which
would increase its utility in the developing world. The core
incremental diagnostic utility of CMR over other methods is left
ventricular (LV) function and late gadolinium enhancement
(LGE) imaging for scar. Previously, we implemented an ultrafast
CMR protocol without contrast in Thailand for the relatively
uncommon indication of iron assessment in a speciﬁc patient
cohort (Thalassemia). Scanning was performed in 8 minutes,
reducing costs 4-fold.13 The purpose of the INCA (Impact of
Non-Invasive CMR Assessment) Peru study was to assess the
potential of faster, cheaper, easier rapid contrast-enhanced
CMR program for wider cardiology indications in an upper
middle-income country.
Methods
The imaging data, analytic methods and study materials of
this study are all anonymized and are available to other
researchers upon (reasonable) request.
Ethics
The research received ethical approval in the United Kingdom:
REC reference: 14/LO/1948, amendment: 3.0, IRAS ID:
142036; University College London REC reference: 11255/
002 and Peru: Edgardo Rebagliati Martins Hospital, Institu-
tional Ethics Committee: IRB No 00003285/Arch 1047, NIT
832–2016–1066. Participants gave written informed consent.
A Peru-International partnership at academic and political
levels was established: UK- UCL and Overseas Development
Ofﬁce; Peru—ESSALUD, The Peruvian Scientiﬁc, Technolog-
ical Development and Technological Innovation (FONDECYT),
Peruvian Society of Cardiology; International: Society for
Cardiovascular Magnetic Resonance (SCMR) and Inter-Amer-
ican Society of Cardiology (SIAC).
Rapid CMR Protocol Development
The protocol (cardiac volumes, function and scar via LGE) was
developed and assessed in 45 participants (33 patients with
cardiomyopathy, 12 healthy volunteers) at Heart Hospital,
London, using a 1.5T scanner (Avanto, SIEMENS Healthineers,
Erlangen Germany), Figure 1. All volunteers had no history of
cardiovascular disease, hypertension or diabetes mellitus, and
were not on regular medications. The protocol included:
1. Localizers, pilot 2 chamber, 3 slice short axis stack, and a
transverse dark blood single shot fast spin echo stack for
anatomic evaluation.
2. Volume and cardiac structure assessment: four, two, three
chamber and aortic valve segmented k-space cine acqui-
sitions.
3. Hand-contrast injection: gadolinium-based contrast agent
Gadoterate meglumine (Dotarem. Guerbet S.A France,
0.1 mmol/kg).
4. Short axis cine stack (7-mm slice thickness, 3 mm inter-
slice gap).
5. Scar imaging: repeating cine views as needed, followed by
an optional sequence to determine the optimal inversion
Clinical Perspective
What Is New?
• Cardiac Magnetic Resonance imaging improves the care of
cardiac patients in high income countries by improving
diagnostic accuracy and better targeting expensive treat-
ments.
• It is, however, too expensive for developing countries.
• We developed and tested a rapid cardiac magnetic
resonance protocol focusing on just measuring cardiac
volumes and scar for deployment on existing scanners in
the developing world.
What Are the Clinical Implications?
• In a trial deployment at 2 sites in a capital city of an upper
middle-income country, rapid cardiac magnetic resonance
could be delivered faster, cheaper, and easier than is
conventionally done.
• The rapid Cardiac Magnetic Resonance protocol was
embedded in clinical care with training and education,
which resulted in important and frequent patient manage-
ment changes that appear beneﬁcial for both patients and
the healthcare system.
• The impression is that resource scarcity is not a justiﬁcation for
the absence of key diagnostic tests in the developing world.
• This protocol is focused on the essential: cardiac volumes
and scar. It can be implemented in a capital city with
existing infrastructure, and it has a major impact for
sustainability if it is delivered with quality, education and
training.
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time and segmented k-space late gadolinium enhance-
ment acquisitions in multiple planes with phase sensitive
and magnitude reconstructions.
Protocol Implementation
We embedded scanning into clinical care and within an
education and mentoring program: 4 professionals from Peru
visited the United Kingdom (2 doctors, 1 technologist, and 1
physicist) for 1 month. Preliminary scanning in Peru was
mentored via live webcasting. A 2-day training course (190
attendees) delivered in Peru for cardiologists, radiologists and
technologists before scanning, followed by a reporting course
(35 radiologists and cardiologists attending) after scanning. In
total, 14 international faculty were involved from Europe, the
United States, and Latin America.
Patients
On the 26th and 27th of November 2016, a total of 100
patients, referred by 10 doctors from 6 centers, underwent
rapid CMR at 2 centers in Lima, Peru: Edgardo Rebagliati
Martins National Hospital (1.5T Avanto, Siemens), and
Delgado Private Hospital (1.5T Aera, Siemens).
CMR Complications
Major complications were predeﬁned as death, resuscitation,
complication requiring admission for at least 1 night. Mild
complications were deﬁned as any others clinically signiﬁcant
events, such as dyspnea, chest pain, and allergic reactions
without shock).
CMR Analysis
Images were analyzed using dedicated software (cvi42, Circle
Cardiovascular Imaging, Calgary Canada). Scans were reported
within 2 days of scanning, during the reporting training course,
with draft reports prepared by fellows (all SCMR level 2
trained) and ﬁnalized by 1 of 4 experts (level 3 trained, J.C.M./
H.L./M.W./J.F.). They were translated into Spanish and
incorporated into the medical records. Scan time was deﬁned
from the timestamp of ﬁrst to the last image acquired.
Image Quality
Images that did not answer the clinical question were
considered poor; those with artifact but still interpretable as
moderate, and images with optimal quality allowing deﬁnitive
assessment of the clinical question were graded as good.
Patient Outcomes
After 12 months, management changes related to CMR results
were reviewed in consultation with general cardiologists or
other physicians (hematologists) in the 6 referral centers. A
change of patient management was reported if CMR resulted in
(1) new diagnosis (eg cardiac amyloidosis diagnosed in a
hypertrophic cardiomyopathy patient) (2) medication changes
(eg suspension of secondary prevention drugs after detection
of myocarditis and nonischemic disease; commencement of
anticoagulation for thrombus) (3) interventional treatment (eg
coronary artery bypass grafting) or (4) new testing (eg, ordering
invasive angiography, biopsy). Many of these resulted in (5)
hospital admission/discharge (eg a large apical thrombus in a
patient with previous RCA infarction).
Cost Evaluation
Reference CMR costs in Peru are difﬁcult to determine given
the complex healthcare structure (public—coverage of 84% of
the population in three sectors; private covering 4% with
multiple insurance companies; 12% uncovered). We took as
reference the average cost from the 2 public and 2 private
Figure 1. Fifteen minutes rapid cardiac magnetic resonance protocol in the United Kingdom. AoV indicates Aortic Valve; CH, Chamber; HASTE,
Half-Fourier acquisition single-shot turbo spin-echo; LOC, Localizer; SAX, Short Axis.
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hospitals offering CMR in Lima.14,15 To determine the cost of
rapid CMR, we included the following parameters: hospital
charges, contrast and cannula costs, and physician, nurse and
technologist fees, but not opportunity cost (eg, displaced MRI
scanning for other organs) or training costs.
Statistical Analysis
Absolute numbers and percentages expressed as meanSD if
they had a normal distribution, and range, if not. Normal
distribution formally tested using Shapiro–Wilk test. Associ-
ation of two categorical variables was analyzed by Chi-square
test. To predict the response of two categories and ordinal
level dependent variables with a set of categorical indepen-
dent variable, binary and ordinal logistic regression analysis
were used, respectively. Values of P<0.05 were considered
statistically signiﬁcant.
Results
The baseline patient characteristics are shown in Table 1.
Patients
One hundred patients were referred, 95 by cardiologists, 5 by
hematologists. 98 were scanned, mean age 52 years (36–
65 years), 60% female. Two underwent repeat scanning (1
due to failure of contrast delivery, 1 to conﬁrm unexpected
cardiac amyloidosis). Indications were: cardiomyopathy (hy-
pertrophic 26%; non-ischemic dilated 22%; ischemic including
viability 15%). There were 12 other indications, Figure 2.
Average scan time was 187 minutes, Table 1. Scan dura-
tion was not inﬂuenced by age (P=0.3).
Before CMR scanning, 94% of patients had undergone
transthoracic echocardiogram, 14% cardiac catheterization,
7% Single-photon emission computed tomography, 3% cardiac
computed tomography; none had had prior CMR.
Scanning
Contrast was administered in 95% of cases with 5 being
evaluated for cardiac iron so not requiring contrast. The
contrast dose was 0.1 mmol/kg (0.2 mL/kg). All studies
were performed without major complication. There was 1
minor complication (panic attack).
Good image quality was reported in 91% of cases, moderate
in 7%. Images were non-diagnostic in 2% and therefore graded
as poor. In reality, the image quality was good but the LGE was
so abnormal that we repeated scanning to conﬁrm that contrast
had actually been administered and that the cases were indeed
cardiac amyloidosis (which they were). Image quality of exam
was not inﬂuenced by age (trend assessed across 4 age
categories: <44, 45–59, 60–74 and >75 year-old, P>0.05).
However, impact on patient care (new diagnosis and change of
medication) was more likely with age (P<0.05), Table 2.
Extra-Cardiac Findings
Incidental extra-cardiac ﬁndings were found in 21% of cases
but were mainly not incrementally important compared with
existing clinical knowledge—2% were judged new important
ﬁndings (example: malignant liver mass). The most common
ﬁndings were: dilated great vessels (13%) and lung parenchy-
mal abnormalities (3%).
Cardiac Findings and Impact
CMR directly impacted clinical management at 12 months in
56% of patients, either by revealing an unsuspected new
diagnosis (19%) and/or leading to a change in management
with therapeutic consequences (37%), Table 3. In 5%, a
change in management was suggested but not delivered due
to access barriers (cardiac surgery or device therapy)—we did
not count these patients in the 56% (ie rapid CMR could have
changed care in 61%).
Figure 3 shows the impact of the rapid CMR on patient
management by the 3 main indications: non-ischemic car-
diomyopathy (hypertrophic cardiomyopathy, dilated cardio-
myopathy); ischemic cardiomyopathy, and other.
Table 1. Patient Baseline and Scan Characteristics
All patients (%) 98 (100%)
Age, mean (range), y 52 (16–93)
Male (%) 39 (40%)
Female (%) 59 (60%)
Height, mean (SD), m 1.62 (0.1)
Weight, mean (SD), kg 69 (11.7)
BMI, mean (SD), kg/m2 24.8 (3.7)
Cardiology referral (%) 93 (95%)
Reader
Cardiologist (%) 69 (70%)
Radiologist (%) 29 (30%)
MRI Scanning duration, mean (SD) 18 (7)
CMR cost $150
CMR exam
Contrast enhanced (%) 93 (95%)
Non-contrast (%) 3 (3%)
Repeated scans (%) 2 (2%)
BMI indicates bone mass index; CMR, cardiac magnetic resonance; MRI, magnetic
resonance imaging.
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Rapid CMR satisﬁed all imaging needs in 89% of patients.
In 7%, where CMR was the ﬁrst imaging technique performed,
no further non-invasive imaging was needed. Figures 4 and 5
show 2 cases demonstrating the impact of CMR on the
management. Although non-blinded, CMR did not miss any
diagnoses initially found by echocardiography.
Cost
The rapid CMR strategy was 3 to 5 times less expensive than
current CMR exams in Peru: costing 62%, 75%, and 81% less
compared with existing public/private (for public) or private
(for insurer) fees.
Discussion
Cardiac MRI is a key diagnostic imaging technology that helps
target often expensive treatments, but uptake is limited in
middle-income countries because, although cardiac enabled
systems are present, barriers exist to delivery. This may result
in the poor targeting of already rationed treatments such as
drugs, surgery, stenting, and device therapy. We did 3 things
to make CMR suitable for major centers in developing world
healthcare systems, using Peru as the exemplar: ﬁrstly,
created national/international support structures for a service
at the political and healthcare system levels; secondly,
created an education/mentoring system for both those
delivering the technology and referrers;and thirdly, by focus-
ing on the core utility of CMR, volumes and scar imaging, we
made CMR faster, cheaper, and easier. We delivered high
quality CMR at 2 (capital city) sites in 2 parts of the healthcare
system on patients from 10 clinicians at 6 sites that was 2 to
3 times faster and 3 to 5 times cheaper than usual and
changed the care in 56% of subjects scanned.
The morbidity and mortality from cardiovascular disease in
the developing world is high.4 Healthcare systems need to be
cost appropriate, accessible, and capable of making a
diagnosis, implementing appropriate therapy and monitoring
that therapy. In cardiology, the key diagnostic tests are the
ECG, echocardiogram, angiography, cardiac CT, and cardiac
MRI, typically embedded in a framework of education,
training, and guidelines/protocols for their delivery and
quality control. In middle-income countries, this hierarchy is
Figure 2. Cardiac pathologies evaluated in the INCA (Impact of Non-Invasive CMR Assessment) Study. CMR indicates cardiac magnetic
resonance.
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typically truncated with absence of the more expensive,
technically demanding tests such as CMR. Echocardiogram is
still the ﬁrst imaging technique option for cardiac patients as
it is portable, inexpensive, and recommended by international
guidelines.16,17 This exam remains the ﬁrst line exam to
assess cardiac structure, but this is not sufﬁcient to get
critical information on causation, risk, therapeutic strategy,
and reversibility across a wide range of diseases. CMR tissue
characterization using the late gadolinium enhancement
technique adds major value in many clinical scenarios,
providing information that cannot be obtained any other
way (myocarditis,18 amyloidosis,19 takotsubo, small apical
thrombi, sarcoid20 for example), risk stratiﬁcation21 and
prognostic information22–24 and is becoming essential in
several key clinical scenarios (chest pain, troponin rise,
normal coronaries, to conﬁrm/refute history of ischemic
scarring, some cardiomyopathies). With forthcoming develop-
ments in cardiac personalized care, an appreciation of
inﬂammation and scarring is likely to prove essential to
arbitrate novel therapies.
With expensive technology, usage patterns should reﬂect
the ratio of capital costs to labor costs that the payee can
bear: so, an MRI scanner operational day in the United
Kingdom may be 12 hours, 6 days a week but 20 hours,
7 days a week in Argentina, for example. Modern MRI
Table 2. Image Indication, Quality, and Impact of Rapid CMR




















1 (3%) 4 (18%) 3 (9%) 4 (40%)
Others (%) 5 (15%) 4 (18%) 5 (16%) 1 (10%)
Image quality
Good (%) 32 (94%) 21 (95%) 27 (85%) 9 (90%)
Moderate (%) 2 (6%) 1 (5%) 3 (9%) 1 (10%)
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CMR indicates cardiac magnetic resonance.
Table 3. Impact of Non-Invasive CMR Assessment on Patient
Management
Impact of INCA (Peru)
All patients 98 (100%)
New diagnosis




Change/addition in medication (%) 23 (23%)
Intervention/surgery (%) 6 (6%)
Invasive angiography/biopsy (%) 4 (4%)
Hospital discharge/admission (%) 3 (3%)
Impact on patient management (%)
(new diagnosis and therapeutic consequences)
55 (56%)
Non-invasive imaging ordered after CMR
Transthoracic—transesophageal echocardiogram (%) 6 (6%)
Cardiac computed tomography (%) 3 (3%)
CMR indicates cardiac magnetic resonance; INCA; Impact of Non-Invasive CMR
Assessment.
Figure 3. Impact of rapid cardiac magnetic reso-
nance on cardiac care and management by indication.
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scanners can all do cardiac MRI with the addition of ECG
gating and proper sequences, the basic examples being
supplied routinely with scanner purchase. However, CMR is
perceived as slow, expensive, and complex, not only for
imager to analyze and interpret, but also to the clinician
“gatekeepers”, who decide whom to refer.
We had previously shown that CMR could be performed
quickly in Thailand13 for a single indication, evaluation of
cardiac iron, in a cohort where the clinical value for mortality
and morbidity of this measurement is established.25 However,
in this ﬁrst pilot project, an approach was taken focusing on
technology delivery with less investment in education and
mentoring. In Peru, a broader landscape was emphasized in a
generalize cohort of patients, where the evaluation of cardiac
function, volumes and scar are important diagnostic criteria.
Some less apparent aspects of the study merit attention.
Firstly, CMR has new technologies (sequences) that make
scanning easier—for example motion corrected (MOCO) late
enhancement sequences. We wanted to install these in Peru
(and test their incremental utility), but the industry waiver
form stipulations made these onerous for the local hospitals
to sign (eg, all liability for sequence use was laid on the
hospital not the manufacturer). Secondly, cultural aspects are
important: we were able to scan on Saturday and Sunday at
both sites, and both cardiologists and radiologists worked
together, but at 1 site, a 1 hour lunch-break was mandated.
Thirdly, we could have delivered 15-minute scanning, focusing
on core utility, but the clinical disease stopped this—we had
decided not to do complex imaging particularly congenital
heart disease, but clinician demand meant that we had
several such cases, increasing scan-length (but also adding to
yield). At one stage, we dropped the aortic valve short axis
view—but we soon realized that this was a step too far as
there are high levels of congenital (bicuspid) and acquired
(stenosis/regurgitation) aortic valve disease in clinical care.
Fourthly, we were not expecting the high clinical utility we
encountered. Focusing on 1 familiar disease, hypertrophic
cardiomyopathy is illuminating: the hypertrophic cardiomy-
opathy referred in Peru was far more extreme than in the
United Kingdom (more hypertrophy, more syndromic, more
scar, and more obstruction). We believe that this reﬂects not a
different disease proﬁle, but the test scarcity—only the most
concerning patients were referred by clinicians.
The images from this rapid CMR had routine and
conventional volumes, mass and ejection fraction quanti-





Figure 4. Fifty-two-year-old personal trainer who complained of shortness of breath and fatigue. Previous echocardiogram showed
hypertrophy. Cardiologist referral suspicious of Fabry’s Disease. CMR study: (A) 4 chamber, (B) 2 chamber cine steady free precession revealed
pleural and pericardial effusion, left ventricle hypertrophy and mild systolic dysfunction and (C) Contrast CMR (LGE: 4, 2, and short axis views)
showed diffuse sub-endocardial enhancement in both ventricles (white arrows), suggestive of Cardiac Amyloidosis (most likely type AL). Labial
salivary gland biopsy revealed (D) Hematoxylin-eosin stain, panoramic view: amyloid tissue inﬁltrating the muscularis mucosae and blood
vessels, (E) Congo red stain, original magniﬁcation 98: Type AL positive Congo red staining. Currently patient is receiving chemotherapy and
continues follow-up in heart failure clinic. Biopsy images shared by courtesy of Dr Jose Luis Arenas Gamio, Pathology Service, Guillermo
Almenara Irigoyen Hospital, Lima—Peru. AL indicates amyloid light-chain; CMR, cardiac magnetic resonance; LGE, late gadolinium
enhancement.
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mileage in alternative and incremental, sometimes superior,
techniques for assessing cardiac function. Feature track-
ing for quantiﬁcation of global left ventricular strain in
patients with Global Longitudinal Strain (GLS) is a fast and
robust technique, carrying important clinical information in
many circumstances26,27 and the myocardial contraction
fraction (stroke volume over myocardial volume) is an
underused indexless measure that imports more prognostic
information than the ejection fraction in many clinical
scenarios.28,29 The cine images acquired in the rapid
protocol are conventional and may also be used for more
advanced analysis even without the use of contrast.
However, specialist software requirements and the incom-
plete development of clinical utilities means this was
outside the key priorities for this study. Development over
time would help its implementation and it would make CMR
even easier to implement.
The clinical utility found in Peru of 56% having changed
care after CMR is somewhat less than demonstrated in
international registries, as European/US registries have
reported that CMR changed care in 61.8% of patients.30,31
However, we would have reached these levels in our study by
including the 5% of patients in which a change in management
was appropriate but not possible due to access barriers.
This study was structured to result in a sustainable service,
however, this requires multiple aspects: Local champions: The
project conducted as a Peruvian fellow (KM) came to learn
CMR in the United Kingdom and wanted to translate CMR to
Peru—her PhD title is “the $100, 15-minute CMR scan”.
Political support: was from the UK Overseas Development
Ofﬁce via the embassy to one of ﬁve the sectors which
administers healthcare in Peru: EsSalud, with scanning in both
the public and private sector. We also were careful to include
software solutions so analysis was not perceived as a barrier.
Education/training in depth: Four Peruvians came to the
United Kingdom to train (a cardiologist, radiologist, technol-
ogist, and physicist). We implemented a 2-day training course
for cardiologists and radiologists with a speciﬁc technologist
track—including lectures delivered by technologists. Partner-
ship: all scanning conducted in partnership (day 1 mainly
overseas technologists; day 2 mainly Peruvian); slots for
attendance at scanning were available to clinicians and all
reporting made by overseas level 3 reporters (expertise is
known to be important32) but within a level 1 reporting course
as a training exercise in partnership, and subsequent free 1-
year membership to an international society. Quality: The
rapid CMR protocol was tested in advance using freely
available video conferencing software. We used low-dose
gadolinium (0.1 mmol/L per kg) for cost and so the blood-
pool was not bright at the time of LGE imaging.33 The CMR
studies were conducted within a safe environment, with only





Figure 5. Sixty-ﬁve-year-old man. History of chronic heart disease and heart failure. Chest pain. No previous angiogram. CMR to assess
viability. A, Cine steady free precession (4 chamber, 2 chamber and short axis views) showed bi-ventricular dilatation and severe systolic
dysfunction. B, Contrast CMR (LGE: 4 and short axis views) revealed sub-endocardial enhancement in the ventricle (see arrows). CMR study
suggests possible multi-vessel CA disease with a low overall infarcted burden: global hibernation or dilated cardiomyopathy as differential
diagnosis. Angiogram study (C through E) revealed triple vessel disease. Pending Coronary Artery Bypass Graft surgery. Angiogram images
shared courtesy of Dr Milder Granados, Cayetano Heredia Hospital, Lima—Peru. CA indicates coronary artery; CMR, cardiac magnetic
resonance; LGE, late gadolinium enhancement.
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of the protocol answered the clinical question in 91% of
studies—we used criteria for quality based not directly on
artifact, but on ability of the scan to answer the clinical
questions. Follow-up: the 12-month outcome adjudication was
to ensure outcomes were not just technical but clinical (care
changed in 56%), to make sure there were not major added
investigations triggered (91% of patients) and to engender
engagement. Since the project ended, a clinical service at the
public hospital is continuing, 2 more public hospitals in Lima
have adopted the rapid CMR protocol (1 of them had never
done CMR before), 2 of them initially scanned 4 to 6 patients
per week and included 2 research programs (1 on HIV
cardiomyopathy, and the other on the effect of chronic
altitude exposure during gestation).
Study Limitations
This protocol did not include advanced magnetic resonance
sequences (there was no mapping, no perfusion, and ﬂow only
for selected cases). Perfusion CMR is a safe, accurate, and
cost-efﬁcient test for inducible ischemia34 with superior or
similar performance compared with SPECT35 or invasive
Fractional ﬂow reserve36 However, as alternatives and delivery
are complex, it is outside the scope of rapid CMR with
currently available infrastructure, although this may change
with the latest sequences and developments over time.37
Finally, outcomes were clinical change in management
rather than objective gold standards (not easily available
when CMR is often that standard). The study is described as
assessing CMR in the developing world, but it is perhaps
better described as in the capital city/leading centers in the
developing world, and we have not unequivocally demon-
strated sustainability.
Conclusions
The advanced diagnostic technique cardiac MRI can be made
faster, cheaper, and easier for deployment in the developing
world. This can be done safely with high diagnostic quality on
existing infrastructure and it changes patients care in most of
cases. Finally, this rapid CMR protocol includes an educa-
tional and support package in order to ensure sustainability.
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